| 1 |
Signatures of mutational processes in human cancer
Australian Pancreatic Cancer Genome Initiative et al. · Nature
Open access |
14 Aug 2013 |
10,284 |
| 2 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei et al. · New England Journal of Medicine
Open access |
27 Sep 2015 |
9,557 |
| 3 |
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine
Open access |
11 May 2011 |
7,927 |
| 4 |
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
5,801 |
| 5 |
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert Louis Ferris et al. · New England Journal of Medicine
Open access |
9 Oct 2016 |
5,189 |
| 6 |
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
4,813 |
| 7 |
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine
Open access |
15 Aug 2012 |
4,645 |
| 8 |
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann Sebastian De Bono et al. · New England Journal of Medicine
Open access |
25 May 2011 |
4,448 |
| 9 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 10 |
AGREE II: advancing guideline development, reporting and evaluation in health care
Melissa C. Brouwers, Michelle E. Kho, George P. Browman et al. · Canadian Medical Association Journal
Open access |
5 Jul 2010 |
3,825 |
| 11 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 12 |
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André et al. · New England Journal of Medicine
Open access |
2 Dec 2020 |
3,130 |
| 13 |
ESPEN guidelines on nutrition in cancer patients
Jann Arends et al. · Clinical Nutrition
Open access |
6 Aug 2016 |
3,121 |
| 14 |
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al. · JAMA
Open access |
20 Jun 2017 |
2,963 |
| 15 |
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,868 |
| 16 |
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
2,590 |
| 17 |
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
Thierry O. Philip, Cesare Guglielmi, Anton Hagenbeek et al. · New England Journal of Medicine
|
7 Dec 1995 |
2,458 |
| 18 |
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
Lorenzo Galluzzi et al. · Cell Death and Differentiation
Open access |
15 Jul 2011 |
2,444 |
| 19 |
International network of cancer genome projects
Jennifer L. Jennings et al. · Nature
Open access256 authors |
13 Apr 2010 |
2,439 |
| 20 |
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik‐Zainal et al. · Nature
Open access |
29 Apr 2016 |
2,395 |
| 21 |
Guidelines and definitions for research on epithelial–mesenchymal transition
Jing Lan Yang et al. · Nature Reviews Molecular Cell Biology
ReviewOpen access |
16 Apr 2020 |
2,379 |
| 22 |
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf et al. · The Lancet
Open access |
May 2012 |
2,123 |
| 23 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 24 |
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik‐Zainal et al. · Cell
Open access |
May 2012 |
2,034 |
| 25 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine et al. · The Lancet Oncology
Open access121 authors |
25 Jul 2017 |
1,891 |
| 26 |
Metastasis: a question of life or death
Patrick Mehlen, Alain Puisieux · Nature reviews. Cancer
Review |
24 May 2006 |
1,882 |
| 27 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al. · The Lancet
|
4 Nov 2011 |
1,861 |
| 28 |
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David Michael Hyman et al. · New England Journal of Medicine
Open access |
19 Aug 2015 |
1,756 |
| 29 |
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al. · Nature
Open access |
15 May 2012 |
1,740 |
| 30 |
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Anne‐Pierre Morel, Marjory Lièvre, Clémence Thomas et al. · PLoS ONE
Open access |
5 Aug 2008 |
1,662 |
| 31 |
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
Andreas du Bois, Alexander Reuß, Eric Pujade‐Lauraine et al. · Cancer
Open access |
2 Feb 2009 |
1,651 |
| 32 |
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo Giovanni Casali et al. · Annals of Oncology
Open access |
28 Mar 2018 |
1,636 |
| 33 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood
Open access |
15 Jun 2010 |
1,589 |
| 34 |
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew Gordon Nicholson, Ming‐Sound Tsao, Mary Beth Beasley et al. · Journal of Thoracic Oncology
Open access |
19 Nov 2021 |
1,582 |
| 35 |
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus et al. · Leukemia
Open access |
3 Mar 2020 |
1,556 |
| 36 |
The Life History of 21 Breast Cancers
Serena Nik‐Zainal et al. · Cell
Open access |
May 2012 |
1,554 |
| 37 |
ESPEN practical guideline: Clinical Nutrition in cancer
Maurizio Muscaritoli et al. · Clinical Nutrition
Open access |
18 Mar 2021 |
1,532 |
| 38 |
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
Pierre Feugier, Ambro van Hoof, Catherine Sebban et al. · Journal of Clinical Oncology
|
2 May 2005 |
1,510 |
| 39 |
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas B. Powles et al. · The Lancet
Open access |
18 Dec 2017 |
1,437 |
| 40 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al. · The Lancet
Open access |
21 Nov 2012 |
1,428 |
| 41 |
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola Hermine Ries et al. · Cancer Cell
Open access |
Jun 2014 |
1,404 |
| 42 |
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
Thierry Conroy et al. · The Lancet Oncology
Open access |
15 Apr 2021 |
1,363 |
| 43 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi Krishna Murthy et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
1,345 |
| 44 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi et al. · The Lancet Oncology
|
8 Aug 2012 |
1,295 |
| 45 |
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Stéphane Depil, Philippe N. Duchateau, Stephan A. Grupp et al. · Nature Reviews Drug Discovery
Review |
3 Jan 2020 |
1,240 |
| 46 |
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale André et al. · Cell
Open access |
29 Nov 2018 |
1,233 |
| 47 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al. · The Lancet Oncology
Open access |
28 Nov 2016 |
1,218 |
| 48 |
Use of MTT colorimetric assay to measure cell activation
Denis Gerlier, Nicole Thomasset · Journal of Immunological Methods
|
Nov 1986 |
1,207 |
| 49 |
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo et al. · Annals of Oncology
Open access |
20 Feb 2019 |
1,200 |
| 50 |
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al. · Journal of Clinical Oncology
|
7 Oct 2020 |
1,199 |